Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
The CPTAC study integrated proteomic and genomic data from 77 breast cancer tumors with the aim of identifying potential biomarkers and therapeutic targets.
Among other aims, the five-year effort hopes to use genomic and proteomic data to better understand patient drug response and the development of resistance.
The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.
The organizations will use proteomics to characterize tumors and compare these proteomic characterizations to other forms of data including genomic profiles.
The sites will collect primary human tumors according to a protocol optimized for proteomics for the NCI's Clinical Proteomic Tumor Analysis Consortium.
The core will serve as a center for receiving, qualifying, processing, and distributing biospecimens to the Clinical Proteomic Tumor Analysis Consortium.
Researchers working onbreast, colorectal, and ovarian cancer highlighted their work, making the case for proteogenomic approaches to cancer research.
The project aims to develop multiple-reaction monitoring mass spec and immuno-MRM mass spec assays for roughly 100 proteins involved in RAS signaling.
From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.